Public health issues of hepatitis C virus infection

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 371-380

  Papatheodoridis, George ^a,b   Hatzakis, Angelos ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hepatitis B and C Public Policy Association   (Greece)

Author keywords

Barriers to therapy; Hepatitis C; Incidence; Prevalence; Screening; Transmission

Indexed keywords

ANTIVIRUS AGENT;

CLINICAL EFFECTIVENESS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; INFECTION RATE; NONHUMAN; PREVALENCE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH PROBLEM; REVIEW; TREATMENT PLANNING; VIRUS TRANSMISSION;

EID: 84870417489     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.012     Document Type: Article

References (59)

1. L.B. Seeff Natural history of hepatitis C Hepatology 26 1997 S21 S28
2. EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
3. C. Hezode Oral combination therapy: future hepatitis C virus treatment? J Hepatol 55 2011 933 935
4. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
5. B.D. Smith, R.L. Morgan, G.A. Beckett, Y. Falck-Ytter, D. Holtzman, and J.W. Ward Hepatitis C Virus testing of persons born during 1945 to 1965: recommendations from the centers for disease control and prevention Ann Intern Med 2012 August 16 [Epub ahead of print]
6. A. Hatzakis, S. Wait, J. Bruix, M. Buti, M. Carballo, and M. Cavaleri The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference J Viral Hepat 18 Suppl. 1 2011 1 16
7. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl. 1 2009 74 81
8. F. Abdel-Aziz, M. Habib, M.K. Mohamed, M. bdel-Hamid, F. Gamil, and S. Madkour Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence Hepatology 32 2000 111 115
9. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
10. European Centre for Disease Prevention and Control (ECDC) Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies September 2010 ECDC technical report, Stockholm
11. I.T. Williams, B.P. Bell, W. Kuhnert, and M.J. Alter Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006 Arch Intern Med 171 2011 242 248
12. G.L. Torre, M.R. Gualano, L. Semyonov, N. Nicolotti, W. Ricciardi, and A. Boccia Hepatitis C Virus infections trends in Italy, 1996-2006 Hepat Mon 11 2011 895 900
13. M. Cornberg, H.A. Razavi, A. Alberti, E. Bernasconi, M. Buti, and C. Cooper A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 Suppl. 2 2011 30 60
14. A.E. Mitchell, H.M. Colvin, and B.R. Palmer Institute of Medicine recommendations for the prevention and control of hepatitis B and C Hepatology 51 2010 729 733
15. M.P. Busch, S.A. Glynn, S.L. Stramer, D.M. Strong, S. Caglioti, and D.J. Wright A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors Transfusion 45 2005 254 264
16. M.J. Alter Epidemiology of hepatitis C virus infection World J Gastroenterol 13 2007 2436 2441
17. P.K. Nelson, B.M. Mathers, B. Cowie, H. Hagan, D. Des Jarlais, and D. Horyniak Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews Lancet 378 2011 571 583
18. S. Kamili, K. Krawczynski, K. McCaustland, X. Li, and M.J. Alter Infectivity of hepatitis C virus in plasma after drying and storing at room temperature Infect Control Hosp Epidemiol 28 2007 519 524
19. M.J. Alter HCV routes of transmission: what goes around comes around Semin Liver Dis 31 2011 340 346
20. M. Jadoul, and G. Barril Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission Contrib Nephrol 176 2012 35 41
21. A.M. Hauri, G.L. Armstrong, and Y.J. Hutin The global burden of disease attributable to contaminated injections given in health care settings Int J STD AIDS 15 2004 7 16
22. C. Frank, M.K. Mohamed, G.T. Strickland, D. Lavanchy, R.R. Arthur, and L.S. Magder The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887 891
23. S.E. Tomkins, J. Elford, T. Nichols, J. Aston, S.J. Cliffe, and K. Roy Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data J Viral Hepat 19 2012 199 204
24. E.A. Roberts, and L. Yeung Maternal-infant transmission of hepatitis C virus infection Hepatology 36 2002 S106 S113
25. R.A. Tohme, and S.D. Holmberg Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52 2010 1497 1505
26. S. Yaphe, N. Bozinoff, R. Kyle, S. Shivkumar, N.P. Pai, and M. Klein Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review Sex Transm Infect 2012 Aug 3 [Epub ahead of print]
27. L. Roels, and A. Rahmel The European experience Transpl Int 24 2011 350 367
28. K.R. Neal, S. Ramsay, B.J. Thomson, and W.L. Irving Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study Gut 56 2007 1098 1104
29. P. Marcellin, F. Pequignot, E. arocque-Astagneau, J.P. Zarski, N. Ganne, and P. Hillon Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption J Hepatol 48 2008 200 207
30. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
31. V. Sypsa, G. Touloumi, G.V. Papatheodoridis, N.C. Tassopoulos, I. Ketikoglou, and I. Vafiadis Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments J Viral Hepat 12 2005 543 550
32. S. Deuffic-Burban, P. Mathurin, and A.J. Valleron Modelling the past, current and future HCV burden in France: detailed analysis and perspectives Stat Methods Med Res 18 2009 233 252
33. M.J. Sweeting, A.D. De, L.J. Brant, H.E. Harris, A.G. Mann, and M.E. Ramsay The burden of hepatitis C in England J Viral Hepat 14 2007 570 576
34. G.L. Davis, J.E. Albright, S.F. Cook, and D.M. Rosenberg Projecting future complications of chronic hepatitis C in the United States Liver Transpl 9 2003 331 338
35. S. Deuffic-Burban, T. Poynard, M.S. Sulkowski, and J.B. Wong Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States J Viral Hepat 14 2007 107 115
36. M. Buti, M.R. San, M. Brosa, J.M. Cabases, M. Medina, and C.M. Angel Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C J Hepatol 42 2005 639 645
37. E. De Larocque-Astagneau, C. Meffre, F. Dubois, C. Pioche, S.Y. Le, and F. Roudot-Thoraval The impact of the prevention programme of hepatitis C over more than a decade: the French experience J Viral Hepat 17 2010 435 443
38. Prevention & control of viral hepatitis infection: framework for global action 2012 WHO
39. N.K. Martin, P. Vickerman, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and M. Hickman Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 54 2011 1137 1144
40. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, and D.J. Goldberg Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
41. C. Cohen, S.D. Holmberg, B.J. McMahon, J.M. Block, C.L. Brosgart, and R.G. Gish Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 18 2011 377 383
42. J.R. Kramer, F. Kanwal, P. Richardson, M. Mei, and H.B. El-Serag Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
43. F.D. Gordon Cost-effectiveness of screening patients for hepatitis C Am J Med 107 1999 36S 40S
44. M. Buti, M.A. Casado, L. Fosbrook, J.B. Wong, and R. Esteban Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C J Hepatol 33 2000 651 658
45. U. Siebert, G. Sroczynski, S. Rossol, J. Wasem, U. Ravens-Sieberer, and B.M. Kurth Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C Gut 52 2003 425 432
46. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
47. T.M. Shehab, S.S. Sonnad, and A.S. Lok Management of hepatitis C patients by primary care physicians in the USA: results of a national survey J Viral Hepat 8 2001 377 383
48. T.M. Shehab, M. Orrego, R. Chunduri, and A.S. Lok Identification and management of hepatitis C patients in primary care clinics Am J Gastroenterol 98 2003 639 644
49. L.J. McGarry, V.S. Pawar, H.R. Panchmatia, J.L. Rubin, G.L. Davis, and Z.M. Younossi Economic model of a birth cohort screening program for hepatitis C virus Hepatology 55 2012 1344 1355
50. D.B. Rein, B.D. Smith, J.S. Wittenborn, S.B. Lesesne, L.D. Wagner, and D.W. Roblin The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings Ann Intern Med 156 2012 263 270
51. C.E. McGowan, and M.W. Fried Barriers to hepatitis C treatment Liver Int 32 Suppl. 1 2012 151 156
52. L. Fraenkel, S. McGraw, S. Wongcharatrawee, and G. Garcia-Tsao What do patients consider when making decisions about treatment for hepatitis C? Am J Med 118 2005 1387 1391
53. S.H. Mehta, B.L. Genberg, J. Astemborski, R. Kavasery, G.D. Kirk, and D. Vlahov Limited uptake of hepatitis C treatment among injection drug users J Community Health 33 2008 126 133
54. A. Doab, C. Treloar, and G.J. Dore Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia Clin Infect Dis 40 Suppl. 5 2005 S313 S320
55. M. Backmund, K. Meyer, Z.M. Von, and D. Eichenlaub Treatment of hepatitis C infection in injection drug users Hepatology 34 2001 188 193
56. M. Backmund, J. Reimer, K. Meyer, J.T. Gerlach, and R. Zachoval Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment Clin Infect Dis 40 Suppl. 5 2005 S330 S335
57. S. Mauss, F. Berger, J. Goelz, B. Jacob, and G. Schmutz A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance Hepatology 40 2004 120 124
58. D.M. Evon, K.M. Simpson, D. Esserman, A. Verma, S. Smith, and M.W. Fried Barriers to accessing care in patients with chronic hepatitis C: the impact of depression Aliment Pharmacol Ther 32 2010 1163 1173
59. S. Zickmund, S.L. Hillis, M.J. Barnett, L. Ippolito, and D.R. LaBrecque Hepatitis C virus-infected patients report communication problems with physicians Hepatology 39 2004 999 1007